Nestlé Health Science is engaged in advancing the role of nutritional therapy to change the course of health for consumers, patients and our partners in healthcare. Through investing in innovation and leveraging leading edge science, it aims to forge a new industry based upon inherently safe nutritional therapies with relevant levels of quality of life benefits and proven clinical and health economic value.
In this context, Nestlé Health Science has made several acquisitions and investments:
Pamlab, acquired in 2013, specialises in medical food products for use under medical supervision in the nutritional management of patients with mild cognitive impairment, depression and diabetic peripheral neuropathy.
Prometheus Laboratories, acquired in 2011, specialises in diagnostics and licensed speciality pharmaceuticals in gastroenterology (GI) and oncology. Read more:
CM&D Pharma, acquired in 2011, specialises in the development of products for patients with chronic conditions like chronic kidney disease and gastrointestinal. Read more:
Vitaflo, acquired in 2010, develops and markets clinical nutritional solutions for infants, children and adults with genetic disorders that affect how food is processed by the body. Read more:
Partnerships & Joint ventures
Nutrition Science Partners Limited (NSP) is a 50/50 joint venture formed between Nestlé Health Science and the pharmaceutical and healthcare group Chi-Med in 2012. NSP focuses on gastrointestinal health and may in the future expand into the metabolic disease and brain health areas.
Accera, in which Nestlé Health Science acquired a minority stake in 2012, specialises in neurodegenerative disorders, like Alzheimer’s Disease.
Vital Foods, in which Nestlé Health Science acquired a minority stake in 2011, is active in the development of kiwifruit-based solutions for gastrointestinal conditions.